¼¼°èÀÇ ±âµµ¾ç¾Ð ±â±â ½ÃÀå
Positive Airway Pressure Devices
»óǰÄÚµå : 1777457
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±âµµ¾ç¾Ð ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 32¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 25¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ±âµµ¾ç¾Ð ±â±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 3.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 32¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®Çϰí ÀÖ´Â ºÎ¹® Áß ÇϳªÀÎ ¿¬¼Ó ±âµµ¾ç¾Ð ±â±â´Â CAGR 2.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚµ¿ ±âµµ¾ç¾Ð ±â±â ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 9,250¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±âµµ¾ç¾Ð ±â±â ½ÃÀåÀº 2024³â¿¡ 6¾ï 9,250¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.7%·Î 2030³â±îÁö 6¾ï 2,840¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±âµµ¾ç¾Ð(PAP) µð¹ÙÀ̽º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±âµµ ¾ç¾Ð(PAP) ±â±â°¡ ¼ö¸é ¹× È£Èí Àå¾Ö Ä¡·á¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

±âµµ ¾ç¾Ð±â(PAP)´Â ¿¬¼ÓÀûÀ̰ųª °¡º¯ÀûÀÎ °¡¾Ð °ø±â È帧À» °ø±ÞÇÏ¿© ±âµµ¸¦ °³¹æµÈ »óÅ·ΠÀ¯ÁöÇϵµ·Ï ¼³°èµÈ ºñħ½ÀÀû È£Èí º¸Á¶ ½Ã½ºÅÛÀÔ´Ï´Ù. ÀÌ ±â±â´Â ÁÖ·Î Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ(OSA), ÁßÃß¼º ¼ö¸é¹«È£ÈíÁõ(CSA), ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ½Å°æ±ÙÀ°Áúȯ µî ¸¸¼º È£Èí±âÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¼ö¸é¹«È£ÈíÁõ°ú È£Èí±âÁúȯÀÇ À¯º´·üÀÌ Àü ¼¼°èÀûÀ¸·Î °è¼Ó Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, PAP ±â±â´Â Çö´ë ÀÇ·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® ÀâÀ¸¸ç ȯÀÚÀÇ °á°ú, ¼ö¸éÀÇ Áú, Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

Àü ¼¼°è ¼ö¸é¹«È£ÈíÁõ ȯÀÚ ¼ö´Â ¾à 10¾ï ¸íÀ¸·Î Ãß»êµÇ¸ç, PAP Ä¡·á´Â Áߵ¿¡¼­ ÁßÁõÀÇ OSA¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·á¹ýÀÔ´Ï´Ù. ¼ö¸é°ú °ü·ÃµÈ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ºñ¸¸À² Áõ°¡, Àå±âÀûÀΠȣÈí º¸Á¶°¡ ÇÊ¿äÇÑ °í·É ȯÀÚÀÇ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 »çÅ´ °æÁõ¿¡¼­ ÁߵÀÇ È£Èí°ï¶õ ȯÀÚ¸¦ À§ÇÑ ºñħ½ÀÀû ÀΰøÈ£ÈíÀÇ Á߿伺À» ºÎ°¢½ÃÄ×À¸¸ç, ÀçÅà ¿ä¾ç ȯ°æ, º´¿ø, ¼ö¸é Ŭ¸®´Ð¿¡¼­ PAP ±â±âÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇß½À´Ï´Ù.

±â¼ú Çõ½ÅÀÌ PAP ±â±âÀÇ ¼º´É°ú ȯÀÚ ¼øÀÀµµ¸¦ ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¾Ð·Â ÀÚµ¿ Á¶Àý, ¼ÒÀ½ Á¦°Å, ¿¬°á¼º, ¸¶½ºÅ© µðÀÚÀÎÀÇ ±â¼úÀû Áøº¸·Î PAP Ä¡·áÀÇ È¿°ú¿Í ȯÀÚÀÇ ¼øÀÀµµ°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. °¡Àå Áß¿äÇÑ µ¹ÆÄ±¸ Áß Çϳª´Â ½Ç½Ã°£ È£Èí ÆÐÅÏ¿¡ µû¶ó ¾Ð·Â ¼öÁØÀ» µ¿ÀûÀ¸·Î º¯°æÇÏ´Â ÀÚµ¿ Á¶Àý½Ä ±âµµ ¾ç¾Ð(APAP) ±â±âÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ ±â±â´Â ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ã۰í, ¼ö¸é Áß ±âµµ ÀúÇ×°ú ºÒÆíÇÔÀ» ÁÙ¿©ÁÖ¸ç, ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ Å« Çõ½ÅÀº ºí·çÅõ½º, Wi-Fi, Ŭ¶ó¿ìµå ±â¹Ý ¸ð´ÏÅ͸µ ½Ã½ºÅÛ µî ½º¸¶Æ® ¿¬°á ±â´ÉÀÇ ÅëÇÕÀÔ´Ï´Ù. ÃֽŠPAP ±â±â´Â ¸ð¹ÙÀÏ ¾Û ¹× ȯÀÚ °ü¸® Ç÷§Æû°ú µ¿±âÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, »ç¿ë »óȲ, ¹«È£Èí À̺¥Æ®, ¸¶½ºÅ© Âø¿ë È¿À²À» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀ» ÅëÇØ ¿ø°Ý ¸ð´ÏÅ͸µ, Á¶±â Ä¡·á Á¶Á¤, Ä¡·á ¼øÀÀµµ Çâ»ó µî ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀϺΠ°í±Þ PAP ¸ðµ¨¿¡´Â AI ±â¹Ý ºÐ¼® ±â´ÉÀ» ÅëÇÕÇÏ¿© °³Àκ° ¸ÂÃã Ä¡·á¹ý Ãßõ ¹× À¯Áö°ü¸® ¿¹Ãø ¾Ë¸²À» Á¦°øÇÏ´Â AI ±â¹Ý ºÐ¼® ±â´ÉÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

¸¶½ºÅ© µðÀÚÀÎÀÇ ÁøÈ­¿Í Æí¾ÈÇÔÀÇ Çâ»óµµ PAP ¿ä¹ý ¼øÀÀµµ Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷üµéÀº °ø±â ´©Ãâ°ú ¾Ð¹ÚÁ¡À» ÁÙÀ̰í, ºÒÆíÇÔ°ú ÇǺΠÀڱؿ¡ ´ëÇÑ ÀϹÝÀûÀΠȯÀÚµéÀÇ ºÒ¸¸¿¡ ´ëÀÀÇϱâ À§ÇØ °¡º±°í Á¢ÃË ¸éÀûÀÌ ÀûÀº Çü»ó±â¾ï Æû Äí¼Ç ¸¶½ºÅ©¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¡½À ±â¼úÀ» PAP ±â±â¿¡ ÅëÇÕÇÏ¿© °ÇÁ¶, ÄÚ ¸·Èû, ÀÎÈÄ¿°À» ¿¹¹æÇϰí Àå±â »ç¿ëÀÚ°¡ Ä¡·á¸¦ ´õ Àß °ßµô ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

PAP ±â±âÀÇ È®ÀåÀ» ÁÖµµÇÏ´Â ½ÃÀå µ¿ÇâÀº?

PAP ±â±â ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä Æ®·»µå Áß Çϳª´Â ÀçÅÃÇü ¼ö¸é¹«È£ÈíÁõ °ü¸® ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ¹× ÀçÅÃÀÇ·á ¸ðµ¨·Î ÀüȯµÊ¿¡ µû¶ó ÈÞ´ë¿ë, »ç¿ëÇϱ⠽±°í ½º¸¶Æ®ÇÏ°Ô ¿¬°áµÇ´Â PAP ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ȯÀÚµéÀÌ °Ë»ç½Ç¿¡¼­ÀÇ ¼ö¸é °Ë»çº¸´Ù Áý¿¡¼­ÀÇ Ä¡·á¸¦ ¼±È£Çϱ⠶§¹®¿¡ ÄÄÆÑÆ®ÇÑ µðÀÚÀÎ, USB ÃæÀü, ¹èÅ͸® ±¸µ¿À¸·Î ÆíÀǼºÀÌ ³ôÀº ¿þ¾î·¯ºí, ¿©Çà ½Ã¿¡µµ Æí¸®ÇÑ PAP ±â±â°¡ äÅõǰí ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ Á᫐ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °Íµµ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü´Â ÀûÀÀÇü PAP ¾Ë°í¸®Áò, AI Áö¿ø ¼ö¸é ÃßÀû, »ýü ¼¾¼­¿¡ ÅõÀÚÇÏ¿© °³ÀÎÀÇ È£Èí ÆÐÅϰú µ¿¹Ý Áúȯ¿¡ µû¸¥ ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±¸°­³» ±â±â³ª »ê¼Ò¿ä¹ý°ú ÅëÇÕµÈ PAP ±â±â µîÀÇ º´¿ë¿ä¹ýÀÇ µîÀåÀ¸·Î º¹ÀâÇÑ ¼ö¸éÈ£ÈíÀå¾Ö ȯÀÚÀÇ Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« È帧Àº PAP Ä¡·áÀÇ ¿ëµµ°¡ ¼ö¸é¹«È£ÈíÁõ Ä¡·á À̿ܿ¡µµ È®´ëµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. PAP ±â±â´Â ¼ö¼ú ÈÄ È£Èí °ü¸®, ½Å°æ±Ù Áúȯ °ü¸®, COVID-19 ÇÕº´Áõ, Æó·Å, ¸¸¼º È£ÈíºÎÀü ȯÀÚÀÇ ºñħ½ÀÀû ÀΰøÈ£Èí±â(NIV) Áö¿ø¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀº º´¿ø ¹× ÁßȯÀÚ½Ç È¯°æ¿¡¼­ PAP ±â±âÀÇ ¿ªÇÒÀ» °­È­ÇÏ°í ±Þ¼º±â ÀÇ·á ¹× ÀÀ±Þ ÀÇ·á ÀÀ¿ë ºÐ¾ß¿¡¼­ PAP ±â±âÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çß½À´Ï´Ù.

¶ÇÇÑ, Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, »óȯ Á¤Ã¥, º¸Çè Àû¿ë È®´ë°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¼ö¸é¹«È£ÈíÁõÀ» °øÁߺ¸°ÇÀÇ Áß¿äÇÑ ¹®Á¦·Î ÀνÄÇϰí ÀÖÀ¸¸ç, PAP Ä¡·á¿¡ ´ëÇÑ º¸Çè Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á¿¡ ´ëÇÑ ÀÇ»çÀÇ ÁöÁö°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹, ij³ª´Ù, µ¶ÀÏ, ÀϺ» µîÀÇ ±¹°¡¿¡¼­´Â °ËÁø ÇÁ·Î±×·¥ °­È­, PAP ±â±â ±¸¸Å º¸Á¶, ¿ø°ÝÀÇ·á ±â¹Ý ¼ö¸éÀå¾Ö Ä¡·áÀÇ ÇÕ¸®È­ µîÀ» ÅëÇØ ½ÃÀå Á¢±Ù¼ºÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

PAP ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±âµµ ¾ç¾Ð±â(PAP) ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ¼ö¸é Àå¾ÖÀÇ À¯º´·ü Áõ°¡, È£Èí Ä¡·á ±â¼úÀÇ ¹ßÀü, ÀçÅÃÀÇ·á ¼Ö·ç¼ÇÀÇ Ã¤Åà Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â Ä¡·áµÇÁö ¾ÊÀº ¼ö¸é¹«È£ÈíÁõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ½ÉÇ÷°ü °Ç°­, ´ç´¢º´, Á¤½Å°Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °ÍÀÔ´Ï´Ù. ¹ÌÁø´Ü OSA°¡ ³úÁ¹Áß, °íÇ÷¾Ð, ÀÎÁö±â´ÉÀúÇÏ À§ÇèÀ» ³ôÀδٴ ġ·á º¸°í°¡ ÀÖ¾î º¸´Ù Àû±ØÀûÀÎ ½ºÅ©¸®´×, Áø´Ü, Á¶±â Ä¡·áÀÇ µµÀÔÀÌ Ã˱¸µÇ°í ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« ¿äÀÎÀº Àα¸ÀÇ °í·ÉÈ­¿Í È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. Àå±â È£Èí ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ³ëÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÚµ¿ ¾Ð·Â Á¶Àý ±â´É, °¡½À ±â´É, ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá °í±Þ PAP ±â±â¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ºÏ¹Ì, À¯·´, Áßµ¿ µîÀÇ Áö¿ª¿¡¼­´Â ºñ¸¸°ú °ü·ÃµÈ ¼ö¸é¹«È£ÈíÁõÀÌ ±ÞÁõÇϰí ÀÖ¾î PAP Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·á ¹× ¿Â¶óÀÎ PAP Ä¡·á °ü¸® Ç÷§ÆûÀÇ È®´ëµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í ¼ö¸é Àü¹®Àǰ¡ °¡»ó Áø·á, ÀçÅà ¼ö¸é °Ë»ç, ¿ø°Ý ±â±â ¸ð´ÏÅ͸µÀ» Á¦°øÇÏ¿© PAP ¿ä¹ýÀ» ´õ¿í Ä£¼÷Çϰí ȯÀÚ Ä£È­ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, E-Commerce Ç÷§Æû°ú ÀÇ·á±â±â ±¸µ¶ ¸ðµ¨À» ÅëÇÑ ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å(DTC) PAP ±â±â ÆÇ¸Å ¹× ·»Å» ¼­ºñ½ºµµ È®´ëÇÏ¿© ½ÃÀå Á¢±Ù¼º°ú ±¸¸Å ÆíÀǼºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ±ÔÁ¦ ¹ßÀü°ú ÀÇ·á±â±â Çõ½ÅÀº PAP ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Á¦Á¶¾÷ü´Â FDA ½ÂÀÎ, CE ÀÎÁõ, ÀÇ·á ¾ÈÀü Ç¥ÁØ Áؼö¿¡ ÁßÁ¡À» µÎ¾î ´õ ³ªÀº ǰÁú º¸Áõ°ú ȯÀÚ ¾ÈÀüÀ» º¸ÀåÇÕ´Ï´Ù. »ýºÐÇØ¼º PAP ÇÊÅÍ, ¼ÒÀ½ °¨¼Ò ±â¼ú, ½º¸¶Æ® ¿¡³ÊÁö È¿À² ±â´ÉÀÇ ÅëÇÕÀº ±â±âÀÇ Áö¼Ó°¡´É¼º°ú ģȯ°æ¼ºÀ» ´õ¿í Çâ»ó½ÃÄÑ ¼¼°è ÇコÄɾîÀÇ Áö¼Ó°¡´É¼º ÀÌ´Ï¼ÅÆ¼ºê¿¡ ºÎÇÕÇÕ´Ï´Ù.

È¿°úÀûÀ̰í ȯÀÚ Ä£È­ÀûÀ̸ç AI·Î °­È­µÈ PAP ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ¼¼°è PAP ±â±â ½ÃÀåÀº ¹«¼± ¿¬°á, ÀûÀÀÇü ¾Ð·Â ¿ä¹ý, ÅëÇÕ ¼ö¸é °Ç°­ ¼Ö·ç¼ÇÀÇ Çõ½ÅÀÌ ¹Ì·¡ÀÇ ±Ëµµ¸¦ Çü¼ºÇϸ鼭 Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¿¬¼Ó½Ä ±âµµ¾ç¾Ð ±â±â, ÀÚµ¿½Ä ±âµµ¾ç¾Ð ±â±â, ¹ÙÀÌ·¹º§ ±âµµ¾ç¾Ð ±â±â), ¿ëµµ(Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ ¿ëµµ, È£ÈíºÎÀü ¿ëµµ, COPD ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÀçÅà ÄÉ¾î ¼³Á¤ ÃÖÁ¾ ¿ëµµ, º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Positive Airway Pressure Devices Market to Reach US$3.2 Billion by 2030

The global market for Positive Airway Pressure Devices estimated at US$2.5 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Continuous Positive Airway Pressure Devices, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Automatic Positive Airway Pressure Devices segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$692.5 Million While China is Forecast to Grow at 6.7% CAGR

The Positive Airway Pressure Devices market in the U.S. is estimated at US$692.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$628.4 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Positive Airway Pressure (PAP) Devices Market - Key Trends & Drivers Summarized

Why Are Positive Airway Pressure (PAP) Devices Essential for Treating Sleep and Respiratory Disorders?

Positive Airway Pressure (PAP) devices are non-invasive respiratory support systems designed to keep the airway open by delivering a continuous or variable stream of pressurized air. These devices are primarily used for treating obstructive sleep apnea (OSA), central sleep apnea (CSA), and chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD) and neuromuscular diseases. As the prevalence of sleep apnea and respiratory conditions continues to rise worldwide, PAP devices have become an essential part of modern healthcare, improving patient outcomes, sleep quality, and overall quality of life.

With an estimated 1 billion people affected by sleep apnea globally, PAP therapy remains the gold standard treatment for moderate to severe OSA. The demand for these devices has surged due to increasing awareness of sleep-related health risks, growing obesity rates, and the rising number of elderly patients requiring long-term respiratory support. Additionally, the COVID-19 pandemic highlighted the importance of non-invasive ventilation for patients with mild to moderate respiratory distress, further boosting the adoption of PAP devices across home care settings, hospitals, and sleep clinics.

How Are Technological Innovations Enhancing PAP Device Performance and Patient Compliance?

Technological advancements in auto-adjusting pressure delivery, noise reduction, connectivity, and mask design have significantly improved the effectiveness and patient adherence of PAP therapy. One of the most important breakthroughs is the development of Auto-Adjusting Positive Airway Pressure (APAP) devices, which dynamically modify pressure levels based on real-time breathing patterns. These devices provide customized therapy, improving patient comfort and reducing the likelihood of airway resistance or discomfort during sleep.

Another major innovation is the integration of smart connectivity features, including Bluetooth, Wi-Fi, and cloud-based monitoring systems. Modern PAP devices can sync with mobile apps and patient management platforms, allowing real-time tracking of usage, apnea events, and mask fit efficiency. This technology benefits both patients and healthcare providers, enabling remote monitoring, early intervention for therapy adjustments, and improved adherence rates. Some advanced PAP models also incorporate AI-driven analytics to provide personalized therapy recommendations and predictive maintenance alerts.

The evolution of mask design and comfort enhancements has also contributed to higher PAP therapy compliance rates. Manufacturers are introducing lightweight, minimal-contact, and memory foam cushion masks that reduce air leakage and pressure points, addressing common patient complaints about discomfort and skin irritation. Additionally, the integration of humidification technology in PAP devices helps prevent dryness, nasal congestion, and throat irritation, making therapy more tolerable for long-term users.

What Market Trends Are Driving the Expansion of PAP Devices?

One of the key trends shaping the PAP device market is the rising adoption of home-based sleep apnea management solutions. As healthcare systems shift toward remote patient monitoring (RPM) and at-home care models, there is increasing demand for portable, user-friendly, and smart-connected PAP devices. Many patients prefer home-based therapy over in-lab sleep studies, driving the adoption of wearable and travel-friendly PAP devices that offer compact designs, USB charging, and battery-powered operation for convenience.

The growing focus on personalized medicine and patient-centric care is also influencing the market. Manufacturers are investing in adaptive PAP algorithms, AI-assisted sleep tracking, and biometric sensors to provide tailored therapy based on individual breathing patterns and comorbid conditions. Additionally, the rise of combination therapies, such as PAP devices integrated with oral appliances or oxygen therapy, is improving treatment outcomes for patients with complex sleep-disordered breathing conditions.

Another major trend is the expansion of PAP therapy applications beyond sleep apnea treatment. PAP devices are increasingly being used for post-surgical respiratory care, neuromuscular disease management, and non-invasive ventilation (NIV) support for patients with COVID-19 complications, pneumonia, and chronic respiratory failure. The pandemic reinforced the role of PAP devices in hospital and ICU settings, accelerating their adoption in acute care and emergency medical applications.

Additionally, government initiatives, reimbursement policies, and insurance coverage expansion are driving market growth. Many healthcare systems now recognize sleep apnea as a major public health issue, leading to broader insurance coverage for PAP therapy and greater physician advocacy for early diagnosis and treatment. Countries such as the U.S., Canada, Germany, and Japan have strengthened screening programs, subsidized PAP device purchases, and streamlined telemedicine-based sleep disorder treatments, further increasing market accessibility.

What Factors Are Driving the Growth of the PAP Device Market?

The growth in the positive airway pressure (PAP) device market is driven by several factors, including rising prevalence of sleep disorders, advancements in respiratory therapy technologies, and increasing adoption of home-based healthcare solutions. One of the primary drivers is the growing awareness of untreated sleep apnea and its impact on cardiovascular health, diabetes, and mental well-being. Studies have linked undiagnosed OSA to increased risks of stroke, hypertension, and cognitive decline, prompting more proactive screening, diagnosis, and early treatment adoption.

Another major factor is the aging population and increased prevalence of respiratory diseases. With more elderly individuals requiring long-term respiratory therapy, there is a rising need for advanced PAP devices equipped with auto-adjusting pressure, humidification, and remote monitoring capabilities. Additionally, obesity-related sleep apnea cases are surging, particularly in regions such as North America, Europe, and the Middle East, further driving demand for PAP therapy solutions.

The expansion of telemedicine and online PAP therapy management platforms is also fueling market growth. Many healthcare providers and sleep specialists now offer virtual consultations, at-home sleep studies, and remote device monitoring, making PAP therapy more accessible and patient-friendly. Additionally, direct-to-consumer (DTC) PAP device sales and rental services have expanded through e-commerce platforms and medical device subscription models, increasing market reach and affordability.

Lastly, regulatory advancements and medical device innovations are playing a significant role in PAP market expansion. Leading manufacturers are focusing on FDA approvals, CE certifications, and compliance with medical safety standards, ensuring better quality assurance and patient safety. The integration of biodegradable PAP filters, noise-reduction technologies, and smart energy-efficient features is further enhancing device sustainability and eco-friendliness, aligning with global healthcare sustainability initiatives.

As the demand for effective, patient-friendly, and AI-enhanced PAP devices continues to grow, the global PAP device market is expected to witness significant expansion, with innovations in wireless connectivity, adaptive pressure therapy, and integrated sleep health solutions shaping its future trajectory.

SCOPE OF STUDY:

The report analyzes the Positive Airway Pressure Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Continuous Positive Airway Pressure Devices, Automatic Positive Airway Pressure Devices, Bi-level Positive Airway Pressure Devices); Application (Obstructive Sleep Apnea Application, Respiratory Failures Application, COPD Application); End-Use (Home Care Settings End-Use, Hospitals & Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â